Daniel Karlin, M.D.

Daniel Karlin, M.D.

Chief Medical OfficeratDefinium Therapeutics· In proxies 2022–2025

Pay in FY2025+201% from the year before · Definium Therapeutics stock +92.4% the same year

Daniel Karlin, M.D. was paid $4.0M in FY2025 (Dec), up 201%. Definium Therapeutics stock rose 92.4% that year.

Pay$100 in the stock at the end of FY21 → $65
Pay is from the Summary Compensation Table of each Definium Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Definium TherapeuticsPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role +55%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?